Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
Show episodes
We love to hear from our listeners. Send us a message. On this week"s episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders. Internal drug develo
We love to hear from our listeners. Send us a message. On this week"s episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of funding. Our conversation c
We love to hear from our listeners. Send us a message. On this week"s episode, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Werner explains why a single engineered tRNA therapy has the potenti
We love to hear from our listeners. Send us a message. On this week"s episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Bio, talks about the company"s post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how he reprioritized the
We love to hear from our listeners. Send us a message. On today"s episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, the company"s use of value-based contracts, and building therapeut
We love to hear from our listeners. Send us a message. On today"s episode I"m speaking with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo Pharmaceuticals, and Onspira Therapeutics informs his leadership at Uniquity, a clinical-stage immuno